Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for KRAS G12C-mutant pancreatic ductal adenocarcinoma, drawn from the whole corpus: 9 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Responses to G12C-selective inhibitors are shallower and shorter in the pancreas than in the lung.
Neither sotorasib nor adagrasib has a pancreatic indication, so access depends on off-label use and trials.
Whether adding a G12C-selective drug to a pan-RAS inhibitor improves on the pan-RAS drug alone is untested.
The group is too small for large randomised trials of its own.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
OS 13.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.